Thyroid Cancer

Instead of undergoing surgery for potential cancer, many people with thyroid nodules can safely opt for surveillance.

Cancer survivors worry about recurrence, but seldom think about their risk for new primaries.

The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.

After being diagnosed with a rare cancer, professional runner Gabriele Grunewald became inspired to start a nonprofit that raised awareness for other rare cancers and empowered those who have them.

Tests like these are growing increasingly important, as TOO results lead to treatment changes about 65 percent of the time and a site treatment change about 35 percent of the time, according to Cancer Genetics.

How much better can I help people now that I have been through it myself?

Patients diagnosed with thyroid cancer before the age of 40 appear to be at the highest risk for age-related diseases, including heart disease and diabetes, compared with their age-matched counterparts.

Expert discusses three promising options to treat patients with medullary thyroid cancer.

Patients who choose not to have their thyroid cancer treated often have feelings of anxiety and isolation, and are at a risk of disengaging from the health care system because they might not feel supported.

A recent study found that some late effects are more prevalent in patients who were diagnosed with thyroid cancer before 40 compared to those who were diagnosed at a later age.

Clinical trial enrollment must become speedier for patients with rare diseases such as anaplastic thyroid cancer, says Maria Cabanillas, M.D.

Encapsulated follicular variant of papillary thyroid cancer may actually not be cancer at all, according to Yuri E. Nikiforov.

Marcia S. Brose discusses Lenvima for patients with progressive radioactive iodine (RAI)-refractory differentiated thyroid cancer.

Danielle Nicosia, a survivor of thyroid cancer, discusses being misdiagnosed.

Nexavar and Lenvima have significantly altered the treatment paradigm for patients with advanced RAI-refractory differentiated thyroid cancer, with combination strategies hoping to further build upon this success.

Bethany Andrews Rhoten, Assistant Professor of Nursing, Vanderbilt University, discusses how patients with cancer can cope with body image issues.

Bethany Andrews Rhoten, Assistant Professor of Nursing, Vanderbilt University, discusses body images among patients and survivors of head and neck cancer.

According to a recent analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than the general population, particularly if they receive adjuvant radiation therapy.

The FDA has granted approval to Lenvima (lenvatinib) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase 3 SELECT trial.

With a deadline of April 14, the FDA will soon make its final approval decision on lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

The latest in cancer prevention, diagnosis & treatment.

Researchers urge restraint when it comes to treating thyroid cancer in children.